The DOI matches its Crossref record.
Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction
Abstract
EXECUTIVE SUMMARY SECTION I: INTRODUCTION, BACKGROUND, AND CONCLUSIONS INTRODUCTION History of Harm Reduction Definitions Nicotine Pharmaceutical Products Regulatory Issues and Authorities Committee Charge and Process Application of Risk Assessment to Tobacco Harm Reduction Operating Precepts PRINCIPLES OF HARM REDUCTION Conceptual Framework for Harm Reduction Applications Comparing Other Harm Reduction Interventions to Those for Smoking Conclusions HISTORICAL PERSPECTIVE AND LESSONS LEARNED Tobacco Marketing: Early Health Claims Health Impact of Low-Yield Products Risk Perception Potential Influence of PREPs on Tobacco Use Behaviors Summary and Relevance to PREPs PRODUCTS FOR TOBACCO EXPOSURE REDUCTION Tobacco and Tobacco Products Pharmaceutical Products Other Potential Harm Reduction Methods: Behavioral Strategies and Tobacco Control Policies Regulation of Exposure Reduction Products THE SCIENTIFIC BASIS FOR PREP ASSESSMENT Tobacco Smoke and Toxicology Exposure and Biomarker Assessment in Humans Nicotine Pharmacology Cancer Cariovascular Disease Nonneoplastic Respiratory Disease Reproductive and Developmental Effects Other Health Effects SURVEILLANCE FOR THE HEALTH AND BEHAVIORAL CONSEQUENCES OF EXPOSURE REDUCTION Existing Tobacco Surveillance Systems Proposed Surveillance System Enhancements Issues and Limitations Regarding Surveillance Systems for Assessing Tobacco-Related Health Outcomes Summary and Recommendations IMPLEMENTATION OF A SCIENCE-BASED POLICY OF HARM REDUCTION Next Steps: An Overview Principles for Regulating Potential Reduced-Exposure Products Summary PRINCIPAL CONCLUSIONS SECTION II: EVIDENCE FOR THE SCIENCE BASE NICOTINE PHARMACOLOGY Basic and Human Pharmacology Pharmacokinetics Pharmacodynamics Research Agenda TOBACCO SMOKE AND TOXICOLOGY Physical and Chemical Characteristics of Tobacco Smoke Toxicity of Tobacco Smoke Assessment of Potential Exposure Reduction Products Synergistic Effects with Other Pollutants Molecular Biology Testing Tools Smokeless Tobacco Toxicity General Research Agenda and Recommendations EXPOSURE AND BIOMARKER ASSESSMENT IN HUMANS External Exposure Assessment: The FTC Method and Questionnaire Data Biomarkers of Exposures Biomarkers Estimating the Biologically Effective Dose Biomarkers of Potential Harm Host Susceptibility Genetic Predispositions to Smoking Addiction Biomarker Assessment for Environmental Tobacco Smoke Exposure Development and Validation of Biomarker Assays, Including Quality Control Conclusions Research Agenda CANCER Mutagenesis and DNA Damage Carinogenesis Tobacco Mutagens and Carcinogens Scientific Methods for Assessing Harm Reduction Strategies Lung Cancer Oropharyngeal Cancers Bladder Cancer Endometrial Cancer Environmental Tobacco Smoke Cigar Smoking Smokeless Tobacco Products Studies of Nicotine Mutagenicity and Carinogenicity Conclusions Research Agenda Special Issues in Study Design CARDIOVASCULAR DISEASE Coronary Heart Disease Extracardiac Vascular Disease Other Variables Influenced by Smoking Surrogate Markers Conclusions Research Agenda NONNEOPLASTIC RESPIRATORY DISEASES Biomarkers of Respiratory Diseases Chronic Obstructive Plumonary Disease Asthma Respiratory Infections Summary and Conclusions Research Agenda REPRODUCTIVE AND DEVELOPMENTAL EFFECTS Fertility Impairment Spontaneous Abortions Placental Complications Preterm Delivery Low Birthweight Sudden Infant Death Syndrome (SIDS) Congenital Malformations Cognitive and Behavioral Deficits in Childhood Fetal Lung Development Smokeless Tobacco Conclusions Recommendations OTHER HEALTH EFFECTS Peptic Ulcers Surgical Wound Healing Inflammatory Bowel Disease Rheumatoid Arthritis Oral Disease Dementia Orthopedic Consequences Ocular Disease Dermatologic Conditions Diabetes Renal Disease Schizophrenia Depression Weight Change Drug Interactions Fire Safety Parkinson's Disease Preeclampsia Summary Recommendations APPENDIXES A PRESENTATIONS AND SUBMISSIONS B COMMITTEE BIOGRAPHICAL SKETCHES C TIME LINE OF TOBACCO EVENTS INDEX
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The lasting impact of childhood health and circumstance
Case, A., Fertig, A., & Paxson, C. (2005) · Journal of Health Economics · doi:10.1016/j.jhealeco.2004.09.008 · Cited by 1,738
Lung cancer in never smokers — a different disease
Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2190 · Cited by 1,608
The Perils of Ignoring History: Big Tobacco Played Dirty and Millions Died. How Similar Is Big Food?
BROWNELL, K. D., & WARNER, K. E. (2009) · The Milbank Quarterly · doi:10.1111/j.1468-0009.2009.00555.x · Cited by 678
Alberg, A. J., Ford, J. G., & Samet, J. M. (2007) · Chest · doi:10.1378/chest.07-1347 · Cited by 626
Benowitz, N. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.3 · Cited by 517
Effect of smokeless tobacco (snus) on smoking and public health in Sweden
Foulds, J., Ramstrom, L., Burke, M., & Fagerström, K. (2003) · Tobacco Control · doi:10.1136/tc.12.4.349 · Cited by 471
Epidemiology of smoking-induced cardiovascular disease
Burns, D. M. (2003) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(03)00079-3 · Cited by 408
Analysis of complex mixtures – Cigarette smoke
Borgerding, M., & Klus, H. (2005) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2005.05.010 · Cited by 386
Capitalism and the Politics of Resignation
Benson, P., & Kirsch, S. (2010) · Current Anthropology · doi:10.1086/653091 · Cited by 368
Effect of Smoking Reduction on Lung Cancer Risk
Godtfredsen, N. S. (2005) · JAMA · doi:10.1001/jama.294.12.1505 · Cited by 275
Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation
Pierce, J. P. (2002) · JAMA · doi:10.1001/jama.288.10.1260 · Cited by 240
Does smoking reduction increase future cessation and decrease disease risk? A qualitative review
Hughes, J., & Carpenter, M. (2006) · Nicotine & Tobacco Research · doi:10.1080/14622200600789726 · Cited by 238
Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products
Carter, L. P., Stitzer, M. L., Henningfield, J. E., O'Connor, R. J., Cummings, K. M., & Hatsukami, D. K. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0948 · Cited by 186
Azzopardi, D., Liu, C., & Murphy, J. (2022) · Drug and Chemical Toxicology · doi:10.1080/01480545.2021.1925691 · Cited by 150
Immunotherapy for the treatment of drug abuse
Kosten, T., & Owens, S. M. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.009 · Cited by 135
Children's health and social mobility.
Case, A., & Paxson, C. H. (2006) · The Future of Children · doi:10.1353/foc.2006.0014 · Cited by 128
Effective tobacco dependence treatment
Fiore, M. C. (2002) · JAMA · doi:10.1001/jama.288.14.1768 · Cited by 97
Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a prospective cohort study
Dobbie, F., Hiscock, R., Leonardi-Bee, J., Murray, S., Shahab, L., Aveyard, P., Coleman, T., McEwen, A., McRobbie, H., Purves, R., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19950 · Cited by 79
Effects of cigarette reduction on cardiovascular risk factors and subjective measures
Hatsukami, D. K., Kotlyar, M., Allen, S., Jensen, J., Li, S., Le, C., & Murphy, S. (2005) · Chest · doi:10.1378/chest.128.4.2528 · Cited by 79
Murphy, J., Gaca, M., Lowe, F., Minet, E., Breheny, D., Prasad, K., Camacho, O., Fearon, I. M., Liu, C., Wright, C., et al. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.09.008 · Cited by 71
Gaworski, C. L. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh083 · Cited by 41
Tobacco addiction and pharmacological interventions
Garrett, B. E., Rose, C. A., & Henningfield, J. E. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.10.1545 · Cited by 32
The Future of the Global Tobacco Treaty Negotiations
Waxman, H. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmsb020030 · Cited by 26
(2009) · doi:10.2139/ssrn.1115333 · Cited by 17
Pentel, P. R., Keyler, D. E., Chen, Y., LeSage, M. G., Dufek, M. B., Le, C., & Leslie, F. M. (2006) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2006.08.001 · Cited by 14
Metadata
- Venue
- National Academies Press eBooks
- Publisher
- National Academies Press
- Published
- 2001-09-17
- OpenAlex
- W2411689377
- Cited by
- 445
- References
- 0
- FWCI
- 63.36
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.